Technology

The Science Behind SynapCore

From raw EEG signals to clinically actionable insights. A transparent, validated, and reproducible diagnostic pipeline built on rigorous scientific methodology.

Signal Processing

From Raw Signal to Clinical Insight

Five deterministic stages transform a multichannel EEG recording into a structured clinical decision support report.

01

Raw EEG Acquisition

Multi-channel EEG recordings captured using standardised clinical protocols. Support for 19-channel 10-20 montage and high-density configurations.

02

Preprocessing

Automated artifact rejection, bandpass filtering (0.5-45 Hz), ICA-based ocular artifact removal, bad channel interpolation, and re-referencing to common average.

03

Feature Extraction

Extraction of spectral power features (delta, theta, alpha, beta, gamma bands), coherence metrics, asymmetry indices, and connectivity measures across electrode pairs.

04

ML Classification

LightGBM gradient-boosted ensemble classifier with optimised hyperparameters. Trained and validated using leave-one-subject-out (LOSO) cross-validation for unbiased generalisation estimates.

05

Clinical Report

Structured clinical decision support report with probability scores, confidence intervals, feature importance visualisation, and normative comparison. Designed for clinician review, not autonomous diagnosis.

Machine Learning

ML Architecture

SynapCore uses LightGBM, a gradient-boosted decision tree ensemble, selected for its interpretability, computational efficiency, and strong performance on structured tabular features extracted from EEG signals.

LightGBM Classifier

Gradient-boosted ensemble optimised for EEG spectral features. Provides feature importance rankings that map directly to neurophysiologically meaningful frequency bands, supporting clinical interpretability.

LOSO Cross-Validation

Leave-one-subject-out validation ensures that no data from the test subject appears during training. This provides the most conservative and clinically realistic estimate of generalisation performance, critical for diagnostic applications where overfitting must be eliminated.

Clinical Relevance

Unlike k-fold validation, LOSO simulates real-world deployment where the model encounters a previously unseen patient. This is why we report LOSO metrics rather than inflated k-fold scores common in EEG-ML literature.

Validation

Performance Metrics

Neuraxis validated on public research datasets using LOSO cross-validation. All metrics are preliminary research results.

MetricNeuraxis-Child v1.0Ages 5-17Neuraxis-Adult v1.0Ages 18-35
AUC0.8450.727
Balanced Accuracy0.802-

Full validation report including sensitivity, specificity and MCC in preparation. All reported metrics are preliminary research results. Research Use Only (RUO).

Data

Research Datasets

Validated on publicly available, peer-reviewed datasets to ensure transparency and reproducibility.

IEEE ADHD Dataset

Full dataset5-17 years

Publicly available paediatric EEG dataset used for ADHD classification research. Multi-channel recordings with clinical ADHD diagnoses. Used as primary training and validation set for Neuraxis-Child.

TDBRAIN

N=72 (subset)18-35 years

Adult EEG dataset from the Twente Database. Selected subset of subjects within the adult ADHD age range. Used for Neuraxis-Adult validation with LOSO cross-validation.

CHBMP

282 subjectsAdult

Cuban Human Brain Mapping Project. Large normative EEG reference dataset used for Z-score normalization and establishing population-level baselines for spectral features.

Pre-Commercial · Research Use Only

Regulatory Pathway

Synaption is committed to achieving full regulatory compliance before any clinical deployment. Current status: pre-commercial, Research Use Only.

IEC 62304

In progress

Software lifecycle management for medical device software. Full traceability from requirements to validation.

CE Mark Class IIa

Planned

European conformity assessment for medical devices with measuring function. Target: EU MDR 2017/745 compliance.

UKCA

Planned

UK Conformity Assessed marking for the UK market post-Brexit. Aligned with CE Mark Class IIa requirements.

FDA 510(k)

Planned

US market clearance pathway. Predicate device identification and substantial equivalence demonstration in preparation.